Clinical trials: Prostate Cancer
Prostate Carcinoma
Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients with Prostate Cancer
This clinical trial aims to design and validate an adaptive virtual consultation tool (AVCT) for men with prostate cancer (PC). An AVCT utilizes health literacy assessments in combination with learning preferences and individual…
- Trial name
- NCT06016504
- Testing
- Health Education, Informational Intervention, Survey Administration
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Localising Occult Prostate Cancer Metastases With Advanced Imaging TEchniques
The investigator prospectively compare diagnostic concordance of whole body multi---parametric Magnetic Resonance Imaging (MRI) with current conventional multi---modality reference standard imaging (CT scan, isotope bone scan…
- Trial name
- LOCATE (NCT02935816)
- Testing
- Whole body MRI
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- University College, London
Prostate Cancer
PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy
The PROPS trial is for men being considered for radiotherapy due to the suspicion that their prostate cancer has recurred following the surgical removal of their prostate (prostatectomy).
- Trial name
- PROPS (NCT02131649)
- Testing
- 18F-FCH PET/MRI Scan
- Where
- 10 sites in Australia, Canada and 1 more
- Volunteers
- 99 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Prostate Cancer
Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer
This study is being done to test the safety of a single high-dose of radiation therapy before radical prostatectomy (removal of the prostate).
- Trial name
- NCT01163448
- Testing
- High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports
This observational study will develop and validate a large language model-assisted workflow for imaging cTNM staging annotation and uncertainty recognition in prostate cancer using Chinese PSMA PET/CT report texts generated…
- Trial name
- PSMA-LLM-cTNM (NCT07707232)
- Testing
- Large Language Model-Assisted Report Annotation
- Where
- China
- Volunteers
- 4,600 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Metastatic Castrate-sensitive Prostate Cancer
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level…
- Trial name
- LIBERTAS (NCT05884398)
- Testing
- Apalutamide, Androgen-deprivation Therapy (ADT)
- Where
- 93 sites in United States, Australia and 7 more
- Volunteers
- 420 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer, High Risk
68 Ga-PSMA for High Risk Prostate Cancer
This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence.
- Trial name
- NCT04614363
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
This is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy.
- Trial name
- PSMA-DaroRT (NCT07649421)
- Testing
- Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT)
- Where
- China
- Volunteers
- 254 people
- Sponsor
- West China Hospital
Prostate Cancer
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
- Trial name
- NCT06450106
- Testing
- STM-416p
- Where
- 4 sites in United States, Australia
- Volunteers
- 18 people
- Sponsor
- SURGE Therapeutics
Prostate Cancer
A Prospective Longitudinal Study of Health-Related Quality of Life in Men With Clinically Localized Prostate Cancer
to prospectively assess the health-related quality of life (HRQOL) changes during the first year after different treatment modalities for localized prostate cancer.
- Trial name
- NCT00777452
- Where
- South Korea
- Volunteers
- 93 people
- Sponsor
- Samsung Medical Center
Metastatic Castration Resistant Prostate Cancer
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
This investigator driven study will examine the safety, tolerability and efficacy of the combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
- Trial name
- PRINCE (NCT03658447)
- Testing
- Pembrolizumab, 177Lu-PSMA
- Where
- 4 sites in Australia
- Volunteers
- 37 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer
RET-Targeted Molecular Imaging Probes in Prostate Cancer
The goal of this observational diagnostic imaging study is to evaluate the value of RET-targeted PET/CT molecular imaging in diagnosing neuroendocrine prostate cancer (NEPC) and in assessing disease activity, treatment response…
- Trial name
- NCT07886138
- Testing
- RET-targeted PET/CT molecular imaging, PSMA-targeted PET/CT imaging
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Breast Neoplasms, Ovarian Neoplasms
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
The purpose of this study is to better understand the genetic causes of cancer and the inherited tendency to develop cancer. To accomplish this, blood specimens and/or saliva samples and/or tumor and normal tissue blocks from…
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00579163
- Where
- United States
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Breast Cancer
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.
- Conditions
- Melanoma, Breast Cancer, Prostate Cancer
- Trial name
- PSX-X04 (NCT00636558)
- Testing
- CVA21
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Viralytics
Prostate Cancer, Prostate Adenocarcinoma
Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01856855
- Testing
- Stereotactic Body Radiation Therapy with Integrated Boost
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- John Fiveash, MD
Prostate Cancer
Atrasentan in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate…
- Trial name
- NCT00046943
- Testing
- atrasentan hydrochloride
- Where
- United States
- Sponsor
- Abbott
Prostate Cancer
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan.
- Trial name
- NCT02559115
- Testing
- 68Ga-RM2 (RM2), PET/CT Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer
Subjects will be asked to participate in this clinical trial to examine the safety of 2-deoxyglucose (an agent which is quite similar to glucose) in the treatment of solid tumors and hormone refractory prostate cancer.
- Trial name
- 2-Deoxyglucose (NCT00633087)
- Testing
- 2-deoxyglucose
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rutgers, The State University of New Jersey
Conditions Influencing Health Status, Healthy
Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome
This randomized pilot phase I trial studies the best way, either expressed prostatic secretion (EPS) or post massage urine (PMU) biomarkers, of predicting biopsy results in patients undergoing prostate biopsy.
- Conditions
- Conditions Influencing Health Status, Healthy, Prostate Cancer
- Trial name
- NCT01441687
- Testing
- laboratory biomarker analysis, transrectal prostate biopsy
- Where
- 5 sites in United States
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center